

ADDENDA AND ERRATA

Acta Cryst. (1997). C53, 394

**3 β ,4 α -Dihydroxy-5 β -androstan-17-one.
Erratum**

MANUELA RAMOS SILVA,^a JOSÉ A. PAIXÃO,^a MARIA-
JOSÉ M. DE ALMEIDA,^a ELISIÁRIO J. TAVARES DA SILVA,^b
MARIA L. SÁ E MELO^b AND ANDRÉ S. CAMPOS NEVES^b

^a*Departamento de Física, Fac. Ciências e Tecnologia,
Universidade de Coimbra, P-3000 Coimbra, Portugal, and*

^b*Laboratório Química Farmacêutica, Fac. de Farmácia,
Universidade de Coimbra, P-3000 Coimbra, Portugal.
E-mail: japaixao@gemini.ci.uc.pt*

(Received 27 January 1997)

An error in technical editing is corrected. In the paper by Ramos Silva, Paixão, de Almeida, Tavares da Silva, Sá e Melo and Campos Neves [*Acta Cryst.* (1996), C52, 2892–2894], the opening sentence of the *Comment* should read ‘As part of a study directed towards developing an efficient strategy for the synthesis of formestane, an irreversible aromatase inhibitor which has been shown to be very effective in the treatment of oestrogen-dependent breast cancer, the title compound, (I), has been synthesized as an intermediate.’